Vericel (US:VCEL) Newsfilter·2024-05-22 12:30Core Viewpoint - Vericel Corporation is actively participating in the healthcare sector, focusing on advanced therapies for sports medicine and severe burn care, and will present at the Leerink Partners Healthcare Crossroads Conference on May 29, 2024 [1]. Company Overview - Vericel Corporation is a leader in advanced therapies for sports medicine and severe burn care, combining biological innovations with medical technologies to create a differentiated portfolio of cell therapies and specialty biologics [3]. - The company markets three key products in the United States: - MACI®: An autologous cellularized scaffold product for repairing full-thickness cartilage defects in the knee [3]. - Epicel®: A permanent skin replacement for treating deep dermal or full-thickness burns covering 30% or more of total body surface area [3]. - NexoBrid®: A biological orphan product for the removal of eschar in adults with deep partial-thickness and/or full-thickness burns, for which Vericel holds exclusive North American rights [3].